CL2011002045A1 - Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica. - Google Patents
Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica.Info
- Publication number
- CL2011002045A1 CL2011002045A1 CL2011002045A CL2011002045A CL2011002045A1 CL 2011002045 A1 CL2011002045 A1 CL 2011002045A1 CL 2011002045 A CL2011002045 A CL 2011002045A CL 2011002045 A CL2011002045 A CL 2011002045A CL 2011002045 A1 CL2011002045 A1 CL 2011002045A1
- Authority
- CL
- Chile
- Prior art keywords
- phenylpent
- cycloalkylamino
- urticaria
- pruritus
- benzamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
UNA FORMA CRISTALINA B DE 3-(DIFLUOROMETIL)-1-METIL-N-(3',4',5'-TRIFLUORO[ 1,1'-BIFENIL]-2-IL)-1LHPIRAZOL- 4-CARBOXAMIDA, LA QUE EN UN DIAGRAMA DE DIFRACCIÓN DE POLVOS POR RAYOS X A 25 °C Y RADIACIÓN CU-KO MUESTRA AL MENOS 3 DE LAS SIGUIENTES REFLEXIONES, CITADAS COMO VALORES 20: 6,2 ± 0,2°, 9,2 ± 0,2°, 13,2 ± 0,2°, 14,9 ± 0,2°, 17,7 ± 0,2°, 18,6 ± 0,2°, 23,1 ± 0,2°, 27,6° ± 0,2°, 30,5 ± 0,2°; UN PROCESO PARA LA PRODUCCIÓN DE LA FORMA CRISTALINA B, AGENTE FITOPROTECTOR Y MÉTODO PARA COMBATIR EL CRECIMIENTO DE PLANTAS NO DESEADAS.<br />
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15497309P | 2009-02-24 | 2009-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011002045A1 true CL2011002045A1 (es) | 2012-01-13 |
Family
ID=42102184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011002045A CL2011002045A1 (es) | 2009-02-24 | 2011-08-23 | Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20120077803A1 (es) |
EP (1) | EP2400953A1 (es) |
JP (1) | JP5425229B2 (es) |
KR (1) | KR20110118830A (es) |
CN (1) | CN102395358A (es) |
AU (1) | AU2010217615C1 (es) |
BR (1) | BRPI1008008A2 (es) |
CA (1) | CA2753330A1 (es) |
CL (1) | CL2011002045A1 (es) |
EA (1) | EA201101207A1 (es) |
IL (1) | IL214731A0 (es) |
MA (1) | MA33059B1 (es) |
MX (1) | MX2011008878A (es) |
SG (1) | SG173758A1 (es) |
TN (1) | TN2011000428A1 (es) |
TW (1) | TW201034674A (es) |
WO (1) | WO2010097381A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2750662T3 (es) * | 2012-10-11 | 2020-03-26 | Nerre Therapeutics Ltd | Orvepitant para el tratamiento del prurito crónico |
US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US8987289B2 (en) * | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
JP2019519592A (ja) * | 2016-06-29 | 2019-07-11 | メンロ セラピューティクス インコーポレイテッド | 様々な掻痒状態を処置するためのニューロキニン−1アンタゴニストの使用 |
MX2021000908A (es) | 2018-07-23 | 2021-06-08 | Trevi Therapeutics Inc | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2728166A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
FR2740040B1 (fr) * | 1995-10-23 | 1997-12-05 | Oreal | Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p |
DE19541283A1 (de) * | 1995-11-06 | 1997-05-07 | Boehringer Ingelheim Kg | Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
MY132550A (en) * | 1996-08-22 | 2007-10-31 | Novartis Ag | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists |
JP3793612B2 (ja) * | 1996-11-28 | 2006-07-05 | 花王株式会社 | 皮膚外用剤 |
WO2002051440A1 (fr) * | 2000-12-22 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Medicaments de combinaison |
JP2003238986A (ja) * | 2002-02-22 | 2003-08-27 | Shiseido Co Ltd | サブスタンスp増加抑制剤 |
ITFI20030113A1 (it) * | 2003-04-24 | 2004-10-25 | Menarini Ricerche Spa | Composti lineari nk-2 antagonisti con caratteristiche basiche e formulazioni che li contengono. |
JO2630B1 (en) * | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
WO2008047709A1 (en) * | 2006-10-16 | 2008-04-24 | Lion Corporation | Nk1 receptor antagonist composition |
EP1938804A1 (en) * | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
US20100316678A1 (en) * | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
-
2010
- 2010-02-23 CN CN2010800166204A patent/CN102395358A/zh active Pending
- 2010-02-23 WO PCT/EP2010/052273 patent/WO2010097381A1/en active Application Filing
- 2010-02-23 AU AU2010217615A patent/AU2010217615C1/en not_active Ceased
- 2010-02-23 EA EA201101207A patent/EA201101207A1/ru unknown
- 2010-02-23 MA MA34113A patent/MA33059B1/fr unknown
- 2010-02-23 EP EP10705862A patent/EP2400953A1/en not_active Withdrawn
- 2010-02-23 JP JP2011550600A patent/JP5425229B2/ja not_active Expired - Fee Related
- 2010-02-23 MX MX2011008878A patent/MX2011008878A/es not_active Application Discontinuation
- 2010-02-23 BR BRPI1008008A patent/BRPI1008008A2/pt not_active IP Right Cessation
- 2010-02-23 US US13/202,741 patent/US20120077803A1/en not_active Abandoned
- 2010-02-23 CA CA2753330A patent/CA2753330A1/en not_active Abandoned
- 2010-02-23 TW TW099105199A patent/TW201034674A/zh unknown
- 2010-02-23 SG SG2011059631A patent/SG173758A1/en unknown
- 2010-02-23 KR KR1020117022270A patent/KR20110118830A/ko not_active Application Discontinuation
-
2011
- 2011-08-18 IL IL214731A patent/IL214731A0/en unknown
- 2011-08-19 TN TN2011000428A patent/TN2011000428A1/fr unknown
- 2011-08-23 CL CL2011002045A patent/CL2011002045A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI1008008A2 (pt) | 2016-02-23 |
SG173758A1 (en) | 2011-09-29 |
TW201034674A (en) | 2010-10-01 |
KR20110118830A (ko) | 2011-11-01 |
TN2011000428A1 (en) | 2013-03-27 |
MX2011008878A (es) | 2011-09-21 |
JP5425229B2 (ja) | 2014-02-26 |
WO2010097381A1 (en) | 2010-09-02 |
AU2010217615A1 (en) | 2011-09-08 |
CA2753330A1 (en) | 2010-09-02 |
AU2010217615C1 (en) | 2013-05-23 |
MA33059B1 (fr) | 2012-02-01 |
CN102395358A (zh) | 2012-03-28 |
EA201101207A1 (ru) | 2012-04-30 |
JP2012518622A (ja) | 2012-08-16 |
US20120077803A1 (en) | 2012-03-29 |
IL214731A0 (en) | 2011-11-30 |
EP2400953A1 (en) | 2012-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011002045A1 (es) | Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica. | |
UY36571A (es) | Combinaciones de compuestos activos | |
ECSP21064100A (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida | |
ECSP12012243A (es) | Combinaciones de compuestos activos | |
MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
UY33980A (es) | Composición plaguicida, solución para la regulación del crecimiento de plantas y método para mejoraro regular el crecimiento de plantas. | |
MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
UY36478A (es) | Composiciones microbianas y metodos para usar para beneficiar el crecimiento de las plantas y tratar la enfermedad de las plantas | |
PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
MX341072B (es) | Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol. | |
CL2008002045A1 (es) | Forma cristalina b de 3-(difluorometil)-1-metil-n-(3',4',5'triofluoro (1,1'-bifenil)-2-il)-h-pirazol-4-carboxamida; procedimiento de preparación de dicha forma cristalina; agente fitoprotector que la contiene y método para combatir el crecimiento de plantas no deseadas. | |
GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
UA113198C2 (xx) | Комбінації активних сполук | |
CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
BR112014003198A2 (pt) | compostos para o tratamento e profilaxia de doença por vírus sincicial respiratório | |
CO7141410A2 (es) | Compuesto heterocíclico nitrogenado | |
MX351864B (es) | Composiciones y metodos para controlar la fusariosis. | |
BR112012023021A2 (pt) | compostos de indazol e seus usos | |
MX2018000421A (es) | Composiciones de retinoides topicos. | |
CR20170267A (es) | Combinaciones de compuestos activos | |
UY36447A (es) | Combinaciones de compuestos activos | |
CR20170269A (es) | Combinaciones de compuestos activos | |
UY36432A (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio) carboxamida y compuesto(s) fungicida(s) | |
CL2011000584A1 (es) | Metodo para proteger una planta de enfermedades de las plantas que comprende como ingrediente activo un compuesto derivado del acido alfametoxifenilacetico; uso de dicho compuesto. | |
BR112014008783A2 (pt) | compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório |